BeiCell Therapeutics
北启生物
BeiCell Therapeutics — known in Chinese as 北启生物 — is a cell-therapy drug developer spun out of Peking University professor Deng Hongkui's lab . The company builds on a chemically induced pluripotent stem-cell platform, or CiPSC, which Deng and his team spent years developing at Peking University's Stem Cell Research Center . ZhenFund, the Beijing-based seed fund, backed BeiCell in two consecutive rounds starting in 2022 and lists it as a flagship "angel project" . Deng himself has since drawn wider recognition: he won the 2024 Future Science Prize in life sciences, was named to TIME's 2025 TIME100 Health list, and in late 2025 was elected to the Chinese Academy of Sciences — with ZhenFund flagging each milestone as validation of its bet on scientist-founders .
AI-generated — may contain errors, please verify.
Coverage
A Whole New World | Z News
We invite you to look back on the past month's "highlight reel" — a look at how our portfolio companies have grown and what's new at ZhenFund.
真格基金·Greener Pastures, First Flickers of Ambition | Z News
The light and shadow grow richer; a story is brewing.
真格基金·2024 Future Science Prize Winners Announced | Z News
Celebrating scientists and honoring the spirit of scientific inquiry.
真格基金·
